Spirox said today that it closed the books on a Series C round worth $45 million for the new device it’s developing to treat nasal obstructions. Spirox, which pulled down an $18.5 million Series B nearly a year ago, said the latest round was led by private equity giant KKR and joined by new investor HealthQuest […]
The world’s largest medical device maker bought the rights to a technology that it hopes can one day develop products for functional endoscopic sinus surgery.
Minneapolis-based Medtronic Inc. (NYSE:MDT) said that the so-called chitosan-dextran gel technology was acquired from Robinson Squidgel Ltd., the University of Adelaide in Australia and the University of Otago in New Zealand.
A Medtronic spokesman declined to provide the purchase price for the technology.